Aquaporin 4 and neuromyelitis optica : The Lancet Neurology
The Lancet Neurology, 05/24/2012
Papadopoulos MC et al. – The discovery of circulating IgG1 antibodies against the astrocyte water channel protein aquaporin 4 (AQP4) and the evidence that AQP4–IgG is involved in the development of neuromyelitis optica revolutionised the understanding of the disease. New drug candidates have emerged, such as aquaporumab, sivelestat, and eculizumab. Despite rapid progress, randomised clinical trials to test new drugs will be challenging because of the small number of individuals with the disorder.